Tocilizumab, a human, anti-interleukin-6-receptor (IL-6R) monoclonal antibody that delays interleukin-6 (IL-6) waving, is now being investigated in many clinical trials due to the excessive and abnormal immune response observed in COVID-19 to associated with ARDS and, in some instances, to fibrosis and extensive lung damage [13]. This evidence concerns the gene IL6 and COVID-19.